New Opportunities for Prevention of Meningococcal Disease
Article Abstract:
Meningococcal conjugate vaccines may have advantages over other meningococcal vaccines. These vaccines protect children against infection with a bacterium called Neisseria meningitidis, which causes meningitis. A study published in 2000 found that three doses of the conjugate vaccine provided protection that lasted for at least one year. This vaccine could benefit the 15 countries in sub-Saharan Africa that have the world's heaviest incidence of meningococcal disease. Other countries would benefit as well, including the US.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Efficacy of meningococcal vaccine and barriers to vaccination
Article Abstract:
The quadrivalent meningococcal vaccine appears to be effective in preventing meningococcal infection but special efforts need to be made to vaccinate young adults. Three separate vaccination campaigns were launched in Gregg County, Texas, after an outbreak of infection caused by the bacterium Neisseria meningitidis in 1994. The vaccine was 85% effective in preventing meningococcal infection, but while 67% of 2- to 4-year-olds were vaccinated, only 20% of 19- to 29-year-olds were vaccinated.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines: A Randomized Controlled Trial in Chile
Article Abstract:
Vaccines against meningococcal disease may be effective but only if the vaccine is based on the strain of bacterium causing the disease. Meningococcal disease is an infection of the membranes surrounding the brain and spinal cord. It is usually caused by a bacterium called Neisseria meningitidis. This bacterium has many different strains, or subtypes. In a study of two meningococcal vaccines, each vaccine was based on a specific strain and was most effective against that strain and less effective against other strains. Vaccines based on the outer-membrane protein 1-OMP should be the best vaccines against serogroup B meningococcal disease.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Safety, Immunogenicity, and Induction of Immunologic Memory by a Serogroup C Meningococcal Conjugate Vaccine in Infants: A Randomized Controlled Trial
- Abstracts: Effectiveness of a violence prevention curriculum among children in elementary school: a randomized controlled trial
- Abstracts: How to use an article evaluating the clinical impact of a computer-based clinical decision support system. Evidence-Based Medicine: Principles for Applying the Users' Guides to Patient Care
- Abstracts: FDA regulation of tobacco advertising and youth smoking: historical, social, and constitutional perspectives. Law as a Tool to Advance the Community's Health